Erschienen in:
18.11.2020 | Concise Research Report
Impact of Metformin on Statin Persistence: a Post Hoc Analysis of a Large Randomized Controlled Trial
verfasst von:
Byron Cheon, MS, Ambuj Kumar, MD, MPH, Athanasios Tsalatsanis, PhD, Kevin Cowart, PharmD, MPH, Ronald R. Magness, PhD, Srinivas M. Tipparaju, PhD, Nicholas W. Carris, PharmD
Erschienen in:
Journal of General Internal Medicine
|
Ausgabe 1/2022
Einloggen, um Zugang zu erhalten
Excerpt
Optimal cardiovascular disease (CVD) risk reduction is impaired by statin-associated muscle symptoms (SAMS).
1‐3 Severe muscle reactions are well accounted for, yet mild-to-moderate myalgia is common and difficult to track. No valid SAMS therapies exist, and management requires trial-and-error with different statins until one is tolerated.
1 …